# 2026-08390: FDA Says Fenoglide Exit Wasn't Safety Scare – Generics Safe

2026-08390, Determination FENOGLIDE (Fenofibrate) Tablets, 40 Milligrams and 120 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-04-30, effective 2026-04-30; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-08390
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08390
- Title: Determination FENOGLIDE (Fenofibrate) Tablets, 40 Milligrams and 120 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 23288
- Published: 2026-04-30
- Effective: 2026-04-30
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Says Fenoglide Exit Wasn't Safety Scare – Generics Safe

## Summary

The FDA has confirmed that FENOGLIDE tablets (40 mg and 120 mg) were not taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions, keeping options open for patients and pharmacies. No changes in cost or availability are expected, so everyone can breathe easy!

## Abstract

The Food and Drug Administration (FDA or Agency) has determined that FENOGLIDE (fenofibrate) tablets, 40 milligrams (mg) and 120 mg, was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

## Effects PRIA read

- Generic Approvals May Continue: benefit, low. The FDA determined that FENOGLIDE (fenofibrate) tablets, 40 mg and 120 mg, were not withdrawn for reasons of safety or effectiveness. Because of that determination, the Agency will not begin procedures to withdraw approval of existing abbreviated new drug applications (ANDAs) that refer to this pro…
- Patient Access and Market Options Preserved: benefit, low. FDA confirmed FENOGLIDE (fenofibrate) tablets, 40 mg and 120 mg, were not removed for safety or effectiveness, and the product remains listed in the Orange Book's "Discontinued Drug Product List" as discontinued for reasons other than safety or effectiveness. The notice says FDA will continue to ap…
- ANDA Applicants May Need Updated Labeling: cost, low. The FDA said that if it determines labeling for FENOGLIDE should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling. This informs generic applicants they may be asked to update labeling to conform with current requirements.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-08390 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/30/2026-08390/determination-fenoglide-fenofibrate-tablets-40-milligrams-and-120-milligrams-was-not-withdrawn-from)
- [2026-08390 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-30/pdf/2026-08390.pdf)

## Related
- [Previous: 2026-08389, Self-Regulatory Organizations; The Fixed Income Clearing Corporation; Notice of…](https://policyrisk.com/federal-register/2026-08389)
- [Next: 2026-08391, Agency Information Collection Activities; Renewal of an Approved Information Co…](https://policyrisk.com/federal-register/2026-08391)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08390 (as of 2026-06-08).
